A New Therapeutic Framework for Atrial Fibrillation Drug Development. Issue 1 (19th June 2020)

• Record Type: Journal Article
• Authors: Ang, Yen-Sin; Rajamani, Sridharan; Haldar, Saptarsi M.; Hüser, Jörg
• Is Part Of: Circulation research. Volume 127:Issue 1(2020)
• Publication Date: 2020-06-19
• Subjects: arrhythmias, cardiac -- atrial fibrillation -- drug development -- precision medicine -- therapeutics; Cardiovascular system -- Periodicals; Blood -- Circulation -- Periodicals; Blood Circulation; Cardiovascular System; Vascular Diseases; Sang -- Circulation -- Périodiques; Appareil cardiovasculaire -- Périodiques; 612.1
• DOI: 10.1161/CIRCRESAHA.120.316576
• Languages: English
• ISSNs: 0009-7330

Abstract

Abstract : Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia and cause of significant morbidity and mortality. Its increasing prevalence in aging societies constitutes a growing challenge to global healthcare systems. Despite substantial unmet needs in AF prevention and treatment, drug developments hitherto have been challenging, and the current pharmaceutical pipeline is nearly empty. In this review, we argue that current drugs for AF are inadequate because of an oversimplified system for patient classification and the development of drugs that do not interdict underlying disease mechanisms. We posit that an improved understanding of AF molecular pathophysiology related to the continuous identification of novel disease-modifying drug targets and an increased appreciation of patient heterogeneity provide a new framework to personalize AF drug development. Together with recent innovations in diagnostics, remote rhythm monitoring, and big data capabilities, we anticipate that adoption of a new framework for patient subsegmentation based on pathophysiological, genetic, and molecular subsets will improve success rates of clinical trials and advance drugs that reduce the individual patient and public health burden of AF.